% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Demleitner:281823,
author = {Demleitner, Antonia F and Gomes, Lucas Caldi and Wenz, Lara
and Tzeplaeff, Laura and Pürner, Dominik and Luib, Elena
and Kunze, Lea and Lingor, Paul},
title = {{A}n {E}xploratory {A}nalysis of {D}ifferential {T}ear
{F}luid mi{RNA}s in {P}atients with {P}arkinson's {D}isease
and {A}typical {P}arkinsonian {S}yndromes.},
journal = {Molecular neurobiology},
volume = {62},
number = {12},
issn = {0893-7648},
address = {Totowa, NJ},
publisher = {Humana Press},
reportid = {DZNE-2025-01204},
pages = {16397 - 16409},
year = {2025},
abstract = {Parkinson's disease (PD), multiple system atrophy (MSA),
and progressive supranuclear palsy (PSP) are
neurodegenerative disorders diagnosed by clinical criteria
with limited diagnostic specificity in early stages.
Diagnostic biomarkers facilitating early and precise
diagnosis are needed. Tear fluid (TF) is an easily
accessible body fluid reflecting pathophysiological changes
in ocular and systemic diseases. In this exploratory study,
we investigate TF as a non-invasive source of
disease-specific miRNAs for PD, MSA, and PSP. We demonstrate
reduced TF production in PD patients. Using a real-time
quantitative PCR-based array targeting 1113 miRNAs, we
identified 55 exclusively expressed in PD, 35 in PSP, and 14
in MSA, respectively. Several of these have previously been
identified in other biofluids. Overrepresentation analysis
of target genes showed apoptotic and cell differentiation
pathways as common targets. While these findings suggest
that miRNA alterations in TF might reflect disease
mechanisms in PD and atypical Parkinsonian syndromes, the
exploratory character of the study combined with the use of
pooled samples, indicates the need for further validation.
The small sample size highlights the importance of follow-up
studies with larger, more definitive cohorts to confirm the
potential of these miRNAs as reliable biomarkers.},
keywords = {Humans / MicroRNAs: metabolism / MicroRNAs: genetics /
Parkinson Disease: genetics / Parkinson Disease: metabolism
/ Male / Female / Aged / Tears: metabolism / Middle Aged /
Multiple System Atrophy: genetics / Parkinsonian Disorders:
genetics / Parkinsonian Disorders: metabolism / Supranuclear
Palsy, Progressive: genetics / Biomarkers: metabolism /
Atypical Parkinsonian syndrome (Other) / Biomarker (Other)
/ MiRNA (Other) / Multiple system atrophy (Other) /
Progressive supranuclear palsy (Other) / Tear fluid (Other)
/ MicroRNAs (NLM Chemicals) / Biomarkers (NLM Chemicals)},
cin = {Clinical Research (Munich)},
ddc = {570},
cid = {I:(DE-2719)1111015},
pnm = {353 - Clinical and Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40758158},
doi = {10.1007/s12035-025-05252-2},
url = {https://pub.dzne.de/record/281823},
}